This company listing is no longer active
DBI Stock Overview
Operates as a biotechnology company in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Deutsche Biotech Innovativ AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.11 |
| 52 Week High | €18.00 |
| 52 Week Low | €1.05 |
| Beta | 0 |
| 1 Month Change | 1.83% |
| 3 Month Change | 0% |
| 1 Year Change | -82.92% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| DBI | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.8% | -2.5% | -2.6% |
| 1Y | -82.9% | -14.2% | 7.1% |
Return vs Industry: DBI underperformed the German Biotechs industry which returned -13.6% over the past year.
Return vs Market: DBI underperformed the German Market which returned 13.3% over the past year.
Price Volatility
| DBI volatility | |
|---|---|
| DBI Average Weekly Movement | 1.8% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: DBI has not had significant price volatility in the past 3 months.
Volatility Over Time: DBI's weekly volatility has decreased from 21% to 2% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | n/a | Bernd Wegener | www.dbi-ag.de |
Deutsche Biotech Innovativ AG operates as a biotechnology company in Germany. The company develops Adrecizumab, an antibody-based therapy that has completed the Phase I/II clinical trial for the treatment of septic shock. It also focuses on the development of various drugs for the treatment of solid tumor, organ failure, rosacea, neurodermatitis, pharyngitis, and Alzheimer's diseases.
Deutsche Biotech Innovativ AG Fundamentals Summary
| DBI fundamental statistics | |
|---|---|
| Market cap | €1.05m |
| Earnings (TTM) | -€1.09m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs DBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DBI income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €1.09m |
| Earnings | -€1.09m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.15 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did DBI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/01 22:23 |
| End of Day Share Price | 2024/10/01 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Deutsche Biotech Innovativ AG is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Simon Scholes | First Berlin Equity Research GmbH |